New Strategy in the Fight Against Bacterial Threats
Bacteria entering the human body can cause a wide range of diseases—from mild infections to life-threatening conditions. Among the most aggressive pathogens are Staphylococcus aureus, enterococci, and mycobacteria, which often lead to severe complications. Traditional treatment methods typically involve simultaneous use of antibiotics and anti-inflammatory drugs, but this approach has its drawbacks. Antibiotics may disrupt the balance of the microbiota, while anti-inflammatory drugs can cause side effects with prolonged use.
In response to these challenges, Russian scientists have proposed an alternative solution. A team of experts from Perm Polytechnic University, together with colleagues from the Institute of Ecology and Genetics of Microorganisms of the Ural Branch of RAS and the Perm Pharmaceutical Academy, has developed a drug that targets both pathogens and inflammation simultaneously.
Leukocyte Complex Production Technology
The innovative treatment is based on a complex of peptides derived from human blood leukocytes. The preparation was produced using donor blood treated with special solutions to prevent clotting. Using centrifugation, researchers separated the leukocytes from other blood components, then subjected them to ultrasonic processing. This step broke down the cell membranes and released biologically active molecules without damaging their structure.
The resulting solution was then purified from cellular debris and sterilized to eliminate unwanted microorganisms. The final stage was lyophilization—a process of freezing and vacuum drying—which preserved the activity of the peptides and produced a stable powder with a high concentration of active substances.
Testing for efficacy and range of action
The developed complex underwent a series of laboratory tests on seven clinically significant types of bacteria, including E. coli, enterococcus, and Staphylococcus aureus. During the experiments, the preparation was diluted in a nutrient medium, with the concentration gradually decreased, and added to samples of pathogenic microorganisms. After 24 hours, researchers evaluated how effectively the product inhibited bacterial growth.
The results showed that the minimum concentration required to stop the growth of Staphylococcus aureus was just 1.5 micrograms per milliliter. Higher doses were needed for other bacteria, but the compound displayed a broad spectrum of antibacterial activity. This opens up potential for its use against various infections, including those caused by antibiotic-resistant strains.
Anti-inflammatory potential of the new compound
In addition to its antibacterial action, scientists assessed the compound’s ability to reduce inflammation. They used a carrageenan-induced edema model in laboratory rats for testing. The animals received the compound half an hour before artificial induction of inflammation, followed by measurements of limb swelling. The treatment reduced the inflammatory response by 62.3%, which was 13% more effective than the standard anti-inflammatory drug nimesulide.
Such results indicate a pronounced dual effect: the compound not only fights infection but also relieves inflammation symptoms, which is especially important in severe bacterial diseases.
Prospects for use and further steps
The unique combination of antibacterial and anti-inflammatory properties makes the leukocyte peptide complex a promising foundation for developing new pharmaceutical formulations. As bacteria become increasingly resistant to traditional antibiotics, such innovations are particularly relevant. Researchers plan to continue working on medications for treating infections accompanied by pronounced inflammation and to conduct clinical trials in humans.
In case you didn’t know, Perm National Research Polytechnic University (PNRPU) is one of Russia’s leading technical universities, established in 1953. The university is actively involved in scientific research in medicine, biotechnology, and environmental science. In recent years, PNRPU has launched major projects in collaboration with the Russian Academy of Sciences and the country’s top pharmaceutical companies. The university hosts modern laboratories equipped with advanced tools for molecular and cellular research. PNRPU faculty and students regularly publish scientific articles in international journals and participate in specialized conferences. Thanks to its interdisciplinary approach, the university successfully implements innovative solutions in practical healthcare. Perm Polytechnic is also renowned for its educational programs for young scientists and professionals. The university places special emphasis on developing partnerships with international research centers. This attracts investment and broadens the scope of scientific research. PNRPU’s contribution to the development of Russian medicine and pharmaceuticals has been recognized with state awards and by the professional community.
